Sunifiram

Sunifiram (DM-235) is an ampakine-like compound and an agonist of AMPA receptor with oral activity. Sunifiram can increase the release of acetylcholine in the rat cerebral cortex and exhibits potent cognitive enhancement effects with better nootropic activity compared to piracetam (HY-B0585) . Sunifiram is promising for research in neurodegenerative diseases such as mild cognitive impairment (MCI) and Alzheimer's disease (AD) [1][2][3][4].

Product Specifications

CAS Number

[314728-85-3]

Product Name Alternative

DM-235

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

IGluR

Type

Reference compound

Related Pathways

Membrane Transporter/Ion Channel; Neuronal Signaling

Applications

Neuroscience-Neurodegeneration

Field of Research

Neurological Disease

Assay Protocol

https://www.medchemexpress.com/Sunifiram.html

Concentration

10mM

Purity

99.87

Solubility

DMSO : ≥ 2.6 mg/mL|H2O : 50 mg/mL (ultrasonic)

Smiles

CCC(N1CCN(C(C2=CC=CC=C2)=O)CC1)=O

Molecular Formula

C14H18N2O2

Molecular Weight

246.30

Precautions

H302, H315, H319, H335

References & Citations

[1]Galeotti N, et al. AMPA-receptor activation is involved in the antiamnesic effect of DM 232 (unifiram) and DM 235 (sunifiram) . Naunyn Schmiedebergs Arch Pharmacol. 2003 Dec;368 (6) :538-45.|[2]Moriguchi S, et al. Novel nootropic drug sunifiram enhances hippocampal synaptic efficacy via glycine-binding site of N-methyl-D-aspartate receptor. Hippocampus. 2013 Jun 3.|[3]Moriguchi S, et al. Novel nootropic drug sunifiram improves cognitive deficits via CaM kinase II and protein kinase C activation in olfactory bulbectomized mice. Behav Brain Res. 2013 Apr 1;242:150-7.|[4]Romanelli M N, et al. Pharmacological characterization of DM232 (unifiram) and DM235 (sunifiram), new potent cognition enhancers[J]. CNS Drug Reviews, 2006, 12 (1) : 39-52.